Ionis-Partnered Hepatitis B Drug Bepirovirsen Receives FDA Breakthrough, Priority Review
IONS has more than doubled off its 52-week low of $28.87.
Summary
Ionis Pharmaceuticals' partner, GSK, announced that the FDA has granted both Breakthrough Therapy Designation and Priority Review to their chronic Hepatitis B drug, Bepirovirsen, with a PDUFA date set for October 26, 2026. This is a significant positive development, as Breakthrough Therapy Designation expedites the development and review process for drugs addressing serious conditions with potential for substantial improvement over existing therapies. Priority Review further shortens the FDA's review period to six months, accelerating the potential market entry. This news is fresh and not redundant with the recent timeline, which focused on other regulatory filings and an 8-K regarding zilganersen. These designations significantly de-risk Bepirovirsen's path to approval and underscore its commercial potential, which is highly beneficial for Ionis due to its partnership stake. Investors will now closely monitor the FDA's review process leading up to the October 2026 PDUFA date.
At the time of this announcement, IONS was trading at $72.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $28.87 to $86.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.